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INTRODUCTION
 Type 2 diabetes being a complex metabolic 
disorder remains an ever-increasing global health 
care issue. While glycemic control is associated 
with reductions in the risk of micro vascular 
complications, the macro vascular benefits of 
glycemic control are not very clear.1 The reason 
might be that the benefits of improved glycemic 
control take a long time to influence the progression 
of atherosclerotic vascular disease.
 There are multiple treatment options available 
for patients with diabetes, many of which are 
either weight neutral, cause weight gain or 
promote weight loss. One of the disadvantage of 
having these multiple treatment options is that, 
the wide range of options may cause problem for 
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ABSTRACT
Background and Objective: GLP-one receptor agonists are amongst the unique antidiabetes medications 
that have significant metabolic and cardiovascular benefits in addition to glucose lowering effect. To best 
of our knowledge, there is no published data on efficacy of liraglutide use among Pakistani population.Our 
objective was to ascertain the efficacy of liraglutide use among type two diabetes patients.
Methods: This retrospective study was conducted at the Endocrinology Clinics of Aga Khan University 
Hospital (AKUH) Karachi, Pakistan during the period from July 01, 2016 to 30th June, 2017. Liraglutide 
was prescribed to 68 obese type two diabetes patients with uncontrolled diabetes taking more than one 
oral medication ± insulin. Starting dose of Liraglutide was 0.6 mg, which was increased to 1.2 mg after 1-2 
weeks with further increment to 1.8 mg/day based on tolerance and individual patient preference. Dose 
of other diabetes medications was adjusted according to clinical judgment whereas Dipeptidyl peptidase-
4(DPP-4) inhibitors were discontinued.
Results: Mean age of cohort was 55 years (SD=10.94 years) with median body mass index of 36.45 kg/m2 
and majority(57.35%) were on a dose of 1.2 mg of Liraglutide per day. Median HbA1c reduced to 7.50% and 
7.40% at three months and six months respectively vs 8.45% at baseline. Mean reduction in weight after 
three month was two kilograms and at six months, it was 1.38 kilograms respectively.
Conclusion: Liraglutide as add on therapy demonstrated favourable HbA1c and weight reduction in obese 
uncontrolled type two Diabetes Pakistani subjects.
KEYWORDS: Glucagon like peptide-1(GLP-1) agonist, Liraglutide, Type 2 diabetes.
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the health care provider to prescribe the optimal 
regimen. In making these decisions, the prescriber 
should consider patient’s disease progression, 
comorbidities, and concomitant treatment.2
 After decades of disappointment in attempting 
to control cardiovascular disease progression in 
type 2 diabetes with careful glycemic control,a 
new found hope that newer drugs, particularly 
the Glucagon like peptide 1 receptor (GLP-1) 
agonist and the sodium glucose co transporter 2 
SGLT-2 inhibitors have cardiovascular benefits 
independent of glycemic control has led to a new 
dimension in the management of type 2 diabetes.3 
Despite its role in glucose homeostasis, the 
GLP-1 receptor is amazingly widely distributed 
throughout the body, including heart. GLP-
1 may exert its effects through both receptor-
dependent and receptor-independent mechanism 
and through the actions of both the intact peptide 
and its metabolites.4 Injectable GLP-1 receptor 
agonist mimics endogenous GLP-1 by stimulating 
pancreatic insulin secretion. They have beneficial 
nonglycemic metabolic effects, notably the 
potential for weight loss.5
 Liraglutide a long acting GLP-1 receptor 
agonist has been approved for the treatment of 
type 2 diabetes.6 To assess the long-term effects 
of liraglutide on cardiovascular outcomes and 
other clinically important events, the Liraglutide 
Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results (LEADER) 
trial was initiated in 2010.1 In the LEADER’s 
trial, 9340 patients with type 2 diabetes at high 
cardiovascular risk were randomized to receive 
the longer-acting drug liraglutide 1.8 mg (or 
maximum tolerated dose) or matching placebo 
once daily and followed for a mean of 3.5 years. 
There was a 23% statistically significant (p-value= 
0.001 for non-inferiority, p-value=0.01 for 
superiority) reduction in the primary end point, 
including a 22% reduction in cardiovascular 
mortality (p-value=0.007) and 15% reduction in 
total mortality (p-value=0.02).3 Gastrointestinal 
adverse effects were more common in the 
patients randomized to liraglutide, the trial 
concluded that the patients in liraglutide group 
had significantly reduced risk of cardiovascular 
events and they had better micro vascular 
outcomes then the group with standard therapy.1 
A few studies have been conducted on South 
Asian population in India and all of these studies 
concluded that, liraglutide significantly improves 
glycemic control with low risk of hypoglycemia 
and is associated with significant weight loss in 
Indian patients with type 2 diabetes mellitus.7 To 
best of our knowledge, there is no published data 
on efficacy of liraglutide use among Pakistani 
population.
 Hence, this study aimed to assess the efficacy of 
liraglutide in terms of glycemic control and weight 
reduction in type 2 diabetes patients Pakistani 
population during routine clinical practice at 
outpatient clinic.
METHODS
 This retrospective study was conducted at the 
Endocrinology Clinics of Aga Khan University 
Hospital (AKUH) Karachi, Pakistan during the 
period from July 01, 2016 to 30th June, 2017. This 
study was approved by the ethical committee 
(Ref. No. 4911-Med-ERC-17) of the Aga Khan 
University.
 Liraglutide was prescribed to 68 obese (BMI 
>23kg/m2) type 2 diabetes patients with 
uncontrolled diabetes (HbA1C>7%). All patients 
were on more than one oral hypoglycemic agents 
with or without insulin. DPP4 inhibitors were 
stopped if patients were on it whereas other 
antidiabetes medication were adjusted according to 
clinical judgment. All patients were advised to start 
0.6 mg/day of liraglutide. An increment in dose up 
to 1.2 mg/day was done after 1-2 weeks which was 
later increased to 1.8 mg/day based on tolerance 
and individual patient preference.
 Patients aged below 16 years, non diabetics, 
having type 1 diabetes, not taking liraglutide were 
excluded from the study. Informed written consent 
was obtained from hospital authorities to use the 
data of patients. No personal detail by any means 
related to any patient was revealed in regard of 
ethical considerations.
 Data of patients taking liraglutide was retrieved 
from hospital medical record maintained by 
Health Information Management System of 
Aga Khan University Hospital after acquiring 
permission. Data collection was done by means 
of a data collection tool specifically designed 
for the study, keeping in mind the indicators/
variables asked from the diabetes patient at the 
time of initial and follow-up visits in the diabetes 
clinic. A research assistant was trained to review 
the files of all the diabetes patients falling under 
the aforementioned timelines by means of a 
data collection tool. Data collection tool mainly 
covered information on demographic details of 
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the patient, duration of diabetes and patients with 
history of Hypertension (taking anti hypertensive 
medication or BP>140/90mmhg on home BP 
monitoring), Dyslipidemia (serum LDL>100 mg/
dl, triglycerides >150mg/dl), Coronary artery 
disease including history of  unstable angina, 
previous history of  Myocardial infarction 
or coronary angioplasty, retinopathy (both 
proliferative and non proliferative) diagnosed 
and treated by ophthalmologist, neuropathy 
(diagnosed on previous visits with compromised 
vibration and pin prick sensation assessed with 
a calibrated tuning fork and 10gm monofilament 
testing) and nephropathy (confirmed by presence 
of albuminuria in urine on 2 or more occasions), 
medication details, changes in glycosylated 
haemoglobin(HbA1C) and weight, any reported 
side effects of liraglutide and history of 
discontinuation if any.
Plan of Analysis: Frequencies with percentages 
were reported for categorical variables for e.g. 
gender, associated comorbids, and associated 
Diabetes complications, medication history before 
adding liraglutide, side effects of Liraglutide 
etc. Mean with standard deviation was reported 
for all symmetrically distributed continuous 
variables while median with inter quartile range 
was reported for all asymmetrically distributed 
variables for e.g. age, duration of comorbids, 
baseline anthropometric measurements such 
as height, weight, BMI, BP, Pulse, HbA1C and 
subsequent followup measurements at three and 
six  months, etc. All the analysis was performed on 
STATA version 12.
RESULTS
 Of the total 68 patients studied, mean age of 
cohort was 55 years (SD=10.94 years). Among 
them 50% were male, having a median diabetes 
duration of 13 years. More than four-fifth of 
our study population had dyslipidemia and 
hypertension and less than 15% had coronary 
Efficacy of Liraglutide in clinical practice
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artery disease (Table-I). Median body mass index 
of our study participants was 36.45 kg/m2, and 
majority of them (57.35%) were on a dose of 1.2 
mg of Liraglutide per day. Study participants were 
mostly on maximum doses of sulfonylureas (44%), 
metformin (94%), DPP-4 inhibitors (49%), basal 
insulin (31%), pre-mixed insulin (28%), basal bolus 
regimen (32%) either alone or in combination before 
addition of Liraglutide to the treatment regimen. 
DPP-4 inhibitors were discontinued in all patients 
once liraglutide was introduced and dosage of 
other antidiabetes medications adjusted. Median 
HbA1c at baseline was 8.45% and it reduced to 
7.50% and 7.40% at three months and six months 
post-Liraglutide respectively. The mean reduction 
in weight after three months of Liraglutide was 2 
kilograms and at six months, it was 1.38 kilograms 
respectively. There was no significant difference 
noted in the systolic and diastolic blood pressures 
and the pulse rate at three and six months from the 
baseline, respectively (Table-I). 
 Side-effects reported after the start of 
Liraglutide were mainly nausea (9%), vomiting 
(6%), diarrhoea (7%) and others (12%) which 
included headache, dizziness and constipation. 
In addition to this, Liraglutide was discontinued 
due to the side effects and cost in about seven 
participants (10%) of our study cohort and 
therefore they were not included in the final 
analysis.
DISCUSSION
 This small scale study verifies that Liraglutide as 
an add on therapy was beneficial for both HbA1c 
and weight reduction in Pakistani subjects with 
Diabetes Mellitus (T2DM). The HbA1c reduction 
at 3 months from baseline in our study was 0.95% 
and 1.05% at 6 months. There was -2.00 ± 3.10 kg 
weight reduction at three months and -1.38 ± 3.27 
kg at 6 months. The HbA1c reduction in our study 
corresponds to the maximum HbA1c reduction 
noted in LEAD -4 trial which showed 1.5 % 
reduction at 1.2 and 1.8 mg of Liraglutide doses 
at 24 weeks of treatment.8 Although the mean 
weight reduction in our study noted at six months 
of treatment was less as anticipated but it was 
comparable to weight reduction in LEAD trials 
which was also less than 3 kg with the exception 
of LEAD-6 which showed a weight reduction of 
3.24 kg.9 The probable explanation to this could be 
that weight loss demonstrated with Liraglutide is 
dose dependant whereas in our study more than 
50% subjects were on 1.2mg doses.10-12 No change 
in systolic, diastolic blood pressures and pulse 
at baselines and at six months post treatment 
from the baseline was noted although this was 
not the primary objective and includes several 
confounding factors like retrospective design, 
medication adherence, operator variability etc. 
Gastrointestinal side effects were the commonly 
reported adverse effects among the study 
participants and seven participants withdrew 
liraglutide owing to these side effects. Financial 
constraints remained an important factor in 
continuing patients on Liraglutide therapy.
 Following the LEADER trial which showed 
significant reduction in the composite outcome 
of the first occurrence of death from CV causes, 
M. Owais Rashid et al.
Table-I: Descriptive analysis of patients on liraglutide.
 S. Variables n = 68 (%)
No.
1 Age* 54.47 ± 10.94
2 Gender
        (a)   Male 34 (50%)
        (b)   Female 34 (50%)
3 Duration of Diabetes* 13 ( 7 – 19)
4 Presence of Dyslipidemia 57 (83.82%)
5 Presence of Hypertension 61 (89.71%)
6 Presence of Coronary 9 (13.24%)
    Artery Disease
7 Presence of Retinopathy 4 (5.90%)
8 Presence of Neuropathy 5 (7.35%)
9 Presence of Nephropathy 3 (4.41%)
10 Body Mass Index (kg/m2)* 36.45 (32.40–41.9)
11 Dose of Liraglutide (mg)
        (a)   0.6 7 (10.29%)
        (b)   1.2 39 (57.35%)
        (c)   1.8 22 (32.35%)
12 Participants on Sulfonylurea 30 (44.12%)
    before liraglutide
13 Participants on Metformin 64 (94.12%)
   before liraglutide
14 Participants on Thiazolidinedione 4 (5.88%)
   before liraglutide
15 Participants on DDP-4 inhibitors 33 (48.53%)
   before liraglutide
16 Participants on Basal Insulin 22 (30.88%)
   before liraglutide
17 Participants on Pre-Mixed Insulin 19 (27.94%)
   before liraglutide
18 Participants on Basal Bolus 22 (32.35%)
   Regimen before liraglutide
19 Creatinine levels of participants * 0.8 (0.7 – 0.95)
non-fatal myocardial infarction or nonfatal stroke 
in T2DM subjects with high CV risk, Liraglutide 
along with other GLP 1 agonists is now 
considered as second line therapy in high risk 
CV patients. The EASD and the ADA updated 
2018 consensus statement for DM management 
in patients with T2 DM encourages use of GLP 1 
receptor agonist and SGLT2 inhibitor for patients 
with clinical cardiovascular disease as an add on 
therapy after metformin.13 The exact mechanism 
influencing the beneficial effects of Liraglutide 
on cardiovascular benefit and weight reduction 
remains unknown but one probable hypotheses 
is reduction in visceral fat, hepatic steatosis and 
systemic inflammation which are considered 
strong contributors for cardiovascular morbidity 
in patients with diabetes.14,15 Bouchi et al. 
demonstrated the Liraglutide efficacy in reducing 
visceral fat and thus ameliorating hepatic 
steatosis, albuminuria and microinflammation in 
T2DM patients along with improved quality of 
life following treatment.16
 This single centre retrospective study is the 
first Pakistani study in evaluating the liraglutide 
efficacy in T2 Diabetes Pakistani subjects. The 
mean duration of diabetes in our study population 
was 13 years but nevertheless there was a mean 
reduction in HbA1c at both three months and 
six months. Kaur et al. in their Liraglutide trial 
highlighted that weight reduction and diabetes 
control was irrespective of the duration of 
diabetes and baseline HbA1c thus concluding 
that liraglutide effectiveness could be achieved 
in patients with long standing diabetes as well.17 
Although favourable HbA1C and weight reduction 
was found at six months post liraglutide several 
confounding factors like diet and physical activity 
could not be controlled due to retrospective design 
of study.
 Despite the effective HbA1c and weight reduction 
Liraglutide remains an expensive treatment 
option for a country like Pakistan where majority 
of the patients do not have medical insurance. 
Since this is a single centre experience, prospective 
studies are required evaluating multiple beneficial 
effects of liraglutide in patients with CV risks and 
baseline albuminuria thus evaluating the new 
cardio protective and renal protective role of this 
drug.
CONCLUSION
 Liraglutide as add on therapy demonstrated 
favourable HbA1c and weight reduction in a real 
life clinical setting of Pakistani Type-2 diabetes 
patients. Despite the efficacy, financial constraints 
remain an important set back in utilizing the 
maximum benefitting effects of this drug.
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Table-II: Comparison of variables from baseline following Liraglutide treatment.
S. Variables At Baseline At 3 months At 6 months
No.
1 HbA1c (at baseline) of participant (%)* 8.45 (7.55-9.45) 7.50 (6.70-8.6) 7.40 (6.70-7.90)
2 Change in weight after three months  - -2.00±3.10 -1.38±3.27
    post-Liraglutide of participants*
3 Systolic Blood Pressure (at baseline) of participants (mmHg)* 138.28±17.11 134.95±23.60 138.07±15.60
4 Diastolic Blood Pressure (at baseline) of participants (mmHg)* 74.42±10.05 72.93±8.80 72.64±11.70
5 Pulse Rate (at baseline) of participants (beats/min)* 89.34±13.50 90.40±14.85 92.14±16.61
6 Side Effects reported by participants post-Liraglutide$:
            1.  Nausea  6 (8.82%)
            2.  Vomiting  4 (5.88%)
            3.  Diarrhea  5 (7.35%)
            4.  Others  8 (11.76%)
7 Liraglutide discontinued due to side effects & cost  7 (10.29%)
Legends used in Table-I & II: * All the continuous variables in the table above have been reported as either mean with 
standard deviation (Mean±SD), if they are symmetrically distributed or as median with interquartile range (Median 
(25th percentile – 75th percentile) if they are asymmetrically distributed.
$ It was a multiple response question and the sum of the percentages will not be equal to 100.
Pak J Med Sci     March - April  2020    Vol. 36   No. 3      www.pjms.org.pk     436
Efficacy of Liraglutide in clinical practice
Pak J Med Sci     March - April  2020    Vol. 36   No. 3      www.pjms.org.pk     437
M. Owais Rashid et al.
REFERENCES
1. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, 
Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular 
Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-
322. doi: 10.1056/NEJMoa1603827
2. Nathan DM. Finding new treatments for diabetes--how 
many, how fast... how good? N Engl J Med. 2007;356(5):437-
440. doi: 10.1056/NEJMp068294
3. Thompson PL, Davis TM. Cardiovascular Effects of 
Glucose-Lowering Therapies for Type 2 Diabetes: New 
Drugs in Perspective. Clin Therap. 2017;39(5):1012-1025. 
doi: 10.1016/j.clinthera.2016.10.008
4. Advani A, Bugyei-Twum A, Connelly KA. Cardiovascular 
Effects of Incretins in Diabetes. Canadian J Diabetes. 
2013;37(5):309-314. doi: 10.1016/j.jcjd.2013.06.010
5. Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic 
clinical effects in weight loss and beyond. Obesity. 
2015;23(6):1119-1129. doi: 10.1002/oby.21107
6. Doggrell SA. Liraglutide, a GLP-1 receptor agonist, 
prevents cardiovascular outcomes in patients with type 2 
diabetes. Evidence-Based Med. 2017;22(1):28. doi: 10.1136/
ebmed-2016-110566
7. Kaur P, Mishra SK, Mithal A, Saxena M, Makkar A, 
Sharma P. Clinical experience with Liraglutide in 196 
patients with type 2 diabetes from a tertiary care center in 
India. Indian J Endocrinol Metab. 2014;18(1):77-82.
8. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, 
Raskin P, et al. LEAD-4 Study Investigators. Efficacy 
and safety of the human glucagon-like peptide-1 
analogliraglutide in combination with metformin and 
thiazolidinedione in patients with type 2 diabetes 
(LEAD-4 Met+ TZD). Diabetes Care. 2009;32(7):1224-
1230. doi: 10.2337/dc08-2124
9. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, 
Brett JH, et al. LEAD-6 Study Group. Liraglutide once a 
day versus exenatide twice a day for type 2 diabetes: a 26-
week randomised, parallel-group, multinational, open-
label trial (LEAD-6). Lancet. 2009;374(9683):39-47. doi: 
10.1016/S0140-6736(09)60659-0
10. Nauck M, Frid A, Hermansen K, Shah NS, Tankova 
T, Mitha IH, et al. Efficacy and safety comparison of 
liraglutide, glimepiride, and placebo, all in combination 
with metformin, in type 2 diabetes: the LEAD (liraglutide 
effect and action in diabetes)-2 study. Diabetes Care. 
2009;32(1):84-90. doi: 10.2337/dc08-1355
11. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, 
Antic S, et al. Liraglutidevs insulin glargine and placebo in 
combination with metformin and sulfonylurea therapy in 
type 2 diabetes mellitus (LEAD-5 met+ SU): A randomised 
controlled trial. Diabetologia. 2009;52(10):2046-2055. doi: 
10.1007/s00125-009-1472-y
12. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, 
Rodriguez-Pattzi H, Olvera-Alvarez, et al. LEAD-3 (Mono) 
Study Group. Liraglutide versus glimepiride monotherapy 
for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, 
phase III, double-blind, parallel-treatment trial. Lancet. 
2009;373(9662):473-481. doi: 10.1016/S0140-6736(08)61246-5
13. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, 
Mingrone G, et al. Management of hyperglycaemia in type 2 
diabetes, 2018. A consensus report by the American Diabetes 
Association (ADA) and the European Association for the 
Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-
2498. doi: 10.1007/s00125-019-4845-x
14. Targher G, Arcaro G. Non-alcoholic fatty liver 
disease and increased risk of cardiovascular disease. 
Atherosclerosis. 2007;191(2):235-240. doi: 10.1016/j.
atherosclerosis.2006.08.021
15. Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow 
S. Association of C-reactive protein with cardiovascular 
disease mortality according to diabetes status: Pooled 
analyses of 25,979 participants from four UK prospective 
cohort studies. Diabetes Care. 2012;35(2):396-403. doi: 
10.2337/dc11-1588
16. Bouchi R, Nakano Y, Fukuda T, Takeuchi T, Murakami 
M, Minami I, et al. Reduction of visceral fat by liraglutide 
is associated with ameliorations of hepatic steatosis, 
albuminuria, and micro-inflammation in type 2 diabetic 
patients with insulin treatment: A randomized control trial. 
Endocr J. 2017;64(3):269-281. doi: 10.1507/endocrj.EJ16-0449
17. Kaur P, Mahendru S, Mithal A. Long-term efficacy of 
liraglutide in Indian patients with Type 2 diabetes in a real-
world setting. Indian J Endocrinol Metab. 2016;20(5):595-
599. doi: 10.4103/2230-8210.183825
Authors’ Contribution:
MO conceived the study.
AK helped in data analysis.
MO and SJ were involved in drafting of manuscript 
and is responsible for integrity of research.
NI did review of manuscript. All authors read and 
approved the final manuscript.
